Xencor Inc XNCR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
-
A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs
-
Xencor Reports First Quarter 2026 Financial Results
-
Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW
-
How to make money from tax-loss selling between now and the end of the year
Trading Information
- Previous Close Price
- $18.81
- Day Range
- $18.82–21.26
- 52-Week Range
- $6.92–21.26
- Bid/Ask
- $20.15 / $20.95
- Shares Outstanding
- 74.14M
- Market Cap
- $1.52B
- Volume/Avg
- 2,379 / 881,477
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 15.68
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 260
- Website
- https://www.xencor.com
Valuation
|
Metric
|
XNCR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.51 |
Price/Sales | 13.39 |
Price/Cash Flow | — |
Price/Earnings
XNCR
Financial Strength
|
Metric
|
XNCR
|
|---|---|
Quick Ratio | 6.22 |
Current Ratio | 6.57 |
Interest Coverage | −5.99 |
Quick Ratio
XNCR
Profitability
|
Metric
|
XNCR
|
|---|---|
Return on Assets (Normalized) | −23.73% |
Return on Equity (Normalized) | −33.33% |
Return on Invested Capital (Normalized) | −27.81% |
Return on Assets
XNCR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|C!>!p^ | LOCK|!Lnb& | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|b#$N$>> | LOCK|#FrjD | $71B | |||
| argenx SE ADR
ARGX
| LOCK|?!j#@h | LOCK|!v | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<bRK!!l | LOCK|%Q | $37B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|CV#<&F | LOCK|^l$C< | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|CC^PtGG$ | LOCK|t^w>b | $26B | |||
| Moderna Inc
MRNA
| LOCK|vwb^<f | LOCK|Lv$ | $24B | |||
| Incyte Corp
INCY
| LOCK|s^sMj$# | LOCK|<#p | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|#%<!PH | LOCK|qp& | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|r?Pg$Y | LOCK|k^ | $16B |
United States